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TamponadeAbstract Introduction: Lung cancer is the most common cause of cancer related death worldwide.
Mostly these tumors present with cough, chest pain weight loss. However, presentation as breast
mass and cardiac tamponade is very rare.
Results: We are presenting a rare case of breast metastasis from primary lung cancer. This case pre-
sented as cardiac tamponade adding to the diagnostic dilemma.
Conclusion: The importance of this case is to highlight molecular proﬁling as an applicable tool to
distinguish extra-mammary metastasis that masquerade as mammary neoplasm thereby preventing
unnecessary need of surgery and radiation therapy.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lung cancer is the most common cause of death from cancer
worldwide [1]. Metastatic dissemination of lung cancer occurs
in 56% of cases at presentation commonly to contra-lateral
lung, liver, bone, adrenals, brain, lymph nodes [2,3]. We report
a unique presentation of a lady with NSCLC with metachro-
nous breast metastasis and cardiac tamponade emphasizingimportance of IHC in differentiation of breast primary and
breast metastasis.
Case report
A 30 year old female presented with complaints of persistent
cough for 4 months. Evaluation with 2 samples of sputum
for acid fast bacilli and chest radiograph was found normal.
She was started on daily regimen of anti-tuberculosis therapy.
After 2 months, she developed dyspnea grade 2 (New York
Heart association classiﬁcation). In our Institute, on evalua-
tion, she was thin built with ECOG performance status 2, with
no known co-morbidities and familial malignancies. Clinical
Figure 1 CECT scan image showing large heterogeneous enhancing mass lesion with speculated margin in lung parenchyma with
marked right sided pleural effusion and pericardial effusion with impending cardiac tamponade.
Figure 2 (a and b) Lymph node section shows an epithelial tumor replacing almost whole of lymphoid tissue and inﬁltrating into
surrounding ﬁbroadipose tissue. (c) Tumor cells show strong nuclear immunostaining for TTF-1, (d) no staining is seen for GCDFP-1.
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Figure 3 (e) Section from breast mass shows an epithelial tumor inﬁltrating into the adjacent parenchyma. Duct is not involved by the
tumor. (f) Tumor cells show strong nuclear staining with TTF-1. (g, h, and j) Tumor is nonreactive with estrogen, progesterone and
Her2 neu antibody.
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level IV of the right side of the neck, 3 · 3 cm mobile hard
right anterior axillary group Lymph Node, with 1 · 1 cm
lymph node in the left anterior axillary group. Breast, thyroid,
chest and abdomen examinations were within normal limits.
Sputum cytology was negative for malignancy. Bronchial
washings showed atypical cells. Excision biopsy of the right
cervical lymph node showed metastatic carcinoma with tumor
cells immunopositive for thyroid transcription factor [TTF-1],
negative for GCDFP-15 (gross cystic disease ﬂuid protein) and
negative for epidermal growth factor receptor (EGFR).
Ultrasound of breast showed right breast ill-deﬁned spiculated
area of 1.9 cm in retroareolar location with dilated ducts in its
periphery and thickened areolar skin. Multiple hyperechoic
nodules were seen in peri areolar location and 7 O’ clock posi-
tion. Right axillary lymph nodes largest of 1.2 cm in short axis
dimension. BIRADS 5 (Breast Imaging and Reporting Data
System), left breast was normal. Ultrasound guided breast
biopsy showed invasive ductal carcinoma negative for estrogen
receptor, progesterone receptor and Her 2 neu status with
immunopositivity for TTF-1. During the course of evaluation
the patient developed dyspnea of grade 4. Contrast enhanced
computed tomography of chest (CECT) revealed 6.2 · 5.2 cm
heterogeneous enhancing mass lesion with speculated margin
in lung parenchyma with marked right sided pleural effusion
and pericardial effusion with impending cardiac tamponade.
Intercostal drainage tube (ICD) was placed at the right side
and pericardiocentesis was done by pigtail catheter. Cytology
of pericardial ﬂuid revealed atypical cells. So the patient was
staged as carcinoma lung stage IV (American joint committee
on cancer-AJCC 7) with breast metastasis.She was treated with 6 cycles of Paclitaxel 175 mg/m2 day 1
and carboplatin AUC5 day 2. Post 6 cycles CECT chest, abdo-
men and pelvis revealed progressive disease in view of new
lesions in the right breast, left chest wall, increase in right pleu-
ral effusion and bilateral iliac bone metastasis.
EGFR and ALK (anaplastic lymphoma kinase) by poly-
merase chain reaction (PCR) was negative. The patient was
started on single agent thrice weekly gemcitabine 1.2 g/m2
day 1, 8, 15. CECT chest, abdomen, pelvis post 3 cycles
revealed progressive disease in view of new lesions in right
lower and left upper lobe of lung. Hence the patient was
started on third line chemotherapy with Geﬁtinib 150 mg
OD and tolerated it well at the time of writing this case report
(see Figs. 1–3).Discussion
Primary breast carcinoma is the most common malignancy in
women worldwide. Metastatic involvement of the breast is a
rarity with a reported frequency of 0.4–1.3%. In a review of
14,000 breast cancer cases between 1907 and 1999, 0.43%
was reported to be metastasis [4]. According to case reports
and case series most common sources of metastasis to breast
are hematological malignancies (leukemia, lymphomas) malig-
nant melanoma, tumors of lung, kidney, ovary, thyroid, small
bowel carcinoids, and colo-rectum [5–8].
Metastasis to breast may be lymphatic or hematogenous.
Lymphatic may be due to initial pleural seeding with chest wall
lymphatic involvement which drains to ipsilateral axillary
lymph nodes and retrograde spread to lymphatic system of
Table 1 Differences between a breast metastasis and primary breast carcinoma.
Metastasis to breast Primary mammary neoplasm
Clinical examination
1. Well circumscribed ﬁrm mobile masses
2. Rapidly growing painless lesion located in subcutaneous tissue
3. Skin involvement, nipple retraction and nipple discharge rare
1. Diffuse irregular mass
2. Prediction for upper outer quadrant of breast
3. Skin involvement, nipple retraction and discharge commonly
seen
Mammography
1. Single, well deﬁned
2. No distortion of adjacent architecture, no spiculation or no microcal-
ciﬁcation, no skin involvement
3. Metastatic breast mass causes minimal proliferation of ﬁbrous tissue
surrounding the lesion hence appears same size on palpation and
mammography
1. Diffuse microcalciﬁcation, architectural distortion, compres-
sion of adjacent ducts, lobules with dermal thickening, periare-
olar thickening characteristic
2. Primary breast cancer causes signiﬁcant ﬁbrous tissue prolifer-
ation, hence mass feels larger on palpation compared to
mammography
Ultrasonogram
1. Hypoechoic, well bordered mass lesion that does not lead to distortion
of adjacent structures
1. Hypoechoic nodular lesion, which is ‘taller than broader’ and
has spiculated margins, posterior acoustic shadowing and
microcalciﬁcations
Histological features
1. Micro-calciﬁcation rarely seen exception serous papillary carcinoma of
ovary metastasis.
2. Elastosis absent
3. Carcinoma in situ not seen
4. Well circumscribed margins
5. Lymph vascular emboli more common
6. Pigmented and intra-nuclear inclusions are common (based on type of
metastasis seen in malignant melanoma and hepatocellular carcinoma)
1. Usually present
2. Usually present
3. Strongly favor primary breast carcinoma
4. Usually inﬁltrating margin
5. Lymph vascular emboli seen less compared to metastasis to
breast
6. Not seen
Immunohistochemistry
Usually May be
Estrogen receptor  +
Progesterone receptor  +
Epidermal growth
Factor receptor
 +
Gross cystic disease
Fluid protein 15
 +
Mammaglobin  +
Cytokeratin 5/6  +
168 B.P. Venkatesulu et al.the breast. In hematogenous metastasis a solitary discrete
lesion is more common.
Tellate features on clinical examination, mammography,
and ultra-sonogram of the breast may be used to delineate pri-
mary mammary neoplasms from extra-mammary metastasis.
Yet cytological and histopathological examination remains
gold standard for differentiation and diagnosis (Table 1).
Immunohistochemistry plays a crucial role in differentia-
tion. TTF-1 is expressed in 68–80% of lung adenocarcinomas
and never reported in breast primary. ER is expressed in 80%
and GCDFP-15 in 45–53% of breast carcinomas. Lung adeno-
carcinoma may show low ER 7.6–14.1% expression. 5.2–15%
lung adenocarcinomas express GCDFP-1. Mammaglobin is
expressed in 48–72.1% mammary adenocarcinomas but stains
negatively in pulmonary adenocarcinoma [9–12].
Conclusion
The importance of this case is to highlight IHC as an able tool
to distinguish extra-mammary metastasis that masquerade as
mammary neoplasm thereby preventing unnecessary need of
surgery and radiation therapy.Disclosures
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